ADORA2A and Parkinson disease: After over a decade of effort applied to xanthine based A2AR antagonists, a derivative KW-6002 (istradefylline, 2) was developed and approved in 2013 as an anti-Parkinson drug in Japan under the brand name Nouriast®.